Cantor Fitzgerald Issues Negative Outlook for VERA Earnings

Key Points

• Cantor Fitzgerald has significantly revised down its FY2025 earnings estimates for Vera Therapeutics from ($2.79) to ($4.40) per share, while maintaining an "Overweight" rating with a price target of $100.00.
• The company's recent quarterly earnings report revealed an EPS of (1.20), falling short of analysts' consensus forecast of (0.82).
• Insider activity showed Director Patrick G. Enright increasing his stake by purchasing 209,393 shares at an average price of $20.87, boosting his total ownership to approximately $74.5 million.

Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Stock analysts at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for Vera Therapeutics in a report issued on Wednesday, August 6th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings of ($4.40) per share for the year, down from their prior estimate of ($2.79). Cantor Fitzgerald currently has a "Overweight" rating and a $100.00 target price on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($2.89) per share. Cantor Fitzgerald also issued estimates for Vera Therapeutics' FY2026 earnings at ($4.42) EPS.

Several other equities research analysts have also recently commented on the company. Wolfe Research reissued a "peer perform" rating on shares of Vera Therapeutics in a report on Monday, August 4th. Scotiabank reissued an "outperform" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. Guggenheim reissued a "buy" rating on shares of Vera Therapeutics in a report on Tuesday, June 3rd. HC Wainwright reissued a "buy" rating and set a $85.00 target price (up previously from $75.00) on shares of Vera Therapeutics in a report on Monday, June 2nd. Finally, Wedbush dropped their target price on Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Vera Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $63.00.

Vera Therapeutics Price Performance

NASDAQ:VERA traded up $0.07 during midday trading on Friday, hitting $19.79. 1,047,828 shares of the stock were exchanged, compared to its average volume of 1,078,886. Vera Therapeutics has a one year low of $18.53 and a one year high of $51.61. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of -5.53 and a beta of 1.17. The business has a 50-day moving average price of $22.97 and a two-hundred day moving average price of $25.08. The company has a current ratio of 17.03, a quick ratio of 27.68 and a debt-to-equity ratio of 0.16.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($1.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.38). During the same quarter in the prior year, the company earned ($0.62) earnings per share.

Institutional Trading of Vera Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC raised its stake in Vera Therapeutics by 30.2% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock valued at $237,247,000 after purchasing an additional 1,300,410 shares during the period. Price T Rowe Associates Inc. MD raised its stake in Vera Therapeutics by 8.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company's stock valued at $114,212,000 after purchasing an additional 377,783 shares during the period. FMR LLC raised its stake in Vera Therapeutics by 9.6% during the 4th quarter. FMR LLC now owns 3,053,126 shares of the company's stock valued at $129,117,000 after purchasing an additional 267,842 shares during the period. Vestal Point Capital LP raised its stake in Vera Therapeutics by 132.6% during the 1st quarter. Vestal Point Capital LP now owns 2,500,000 shares of the company's stock valued at $60,050,000 after purchasing an additional 1,425,000 shares during the period. Finally, T. Rowe Price Investment Management Inc. raised its stake in Vera Therapeutics by 18.4% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,675,367 shares of the company's stock valued at $40,243,000 after purchasing an additional 260,188 shares during the period. 99.21% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Patrick G. Enright purchased 209,393 shares of the company's stock in a transaction on Monday, June 23rd. The shares were bought at an average price of $20.87 per share, with a total value of $4,370,031.91. Following the completion of the acquisition, the director owned 3,569,522 shares of the company's stock, valued at approximately $74,495,924.14. This represents a 6.23% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 16.30% of the company's stock.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.